ARM
Arm today announced the appointment of new Board members Karen Dykstra, former Chief Financial and Administrative Officer of AOL and Jeff Sine, Co-Founder and Partner of Raine Group, effective immediately. These highly qualified leaders bring a diverse range of expertise to Arm as the company prepares for a potential public listing.
Arm Chief Executive Officer (CEO) Rene Haas said: “I extend a warm welcome to Karen and Jeff, both exceptional business leaders who will bring a depth and breadth of experience to the Arm Board.”
Arm also today announced the appointment of Jason Child as Chief Financial Officer (CFO). Child has more than 30 years of experience in leadership at high growth companies and scaling global finance functions. Child will join Arm on November 2, 2022 and lead the company’s global finance and IT organizations, reporting to Haas.
Haas added, “Jason is an experienced leader in global finance and technology. His extensive experience in financial management at public companies and IPO execution will be invaluable in preparation for a potential public listing. I look forward to working with him as part of the Arm leadership team as we continue to define the future of computing, built on Arm.”
Child will replace current CFO Inder Singh who will remain at Arm in an advisory role and assist in the transition through November before moving to a new opportunity.
Haas said, “I’d like to thank Inder for his contributions and leadership over these past few years. He has helped the company navigate many changes since joining in 2019, including building a strong organization with upgraded systems and processes in the finance, IT and cybersecurity teams. We wish him all the best moving forward.”
Child most recently served as senior vice president and CFO at Splunk from 2019. Prior to Splunk, Child held multiple CFO positions including at Groupon, which he helped to take public in 2011 and as CFO at Amazon International.
“Since its founding, Arm has had an incredible history of innovation and leadership in the semi-conductor industry,” said Child. “Arm is a world-class, category leader and I am thrilled to join as CFO during this exciting time for the company.”
About Karen Dykstra
Ms. Dykstra previously served as Chief Financial and Administrative Officer of AOL, a web portal and online service provider. Prior to AOL, she was a Partner at Plainfield Asset Management, and served as Chief Operating Officer and Chief Financial Officer of Plainfield Direct, Plainfield’s business development company. She previously spent over 25 years with Automatic Data Processing (ADP), a provider of human capital management solutions to employers, serving most recently as Chief Financial Officer. Ms. Dykstra is currently a director on the boards of VMware and Gartner, and has also served on the boards of Boston Properties, Crane and AOL.
About Jeff Sine
Mr. Sine is the Co-Founder and Partner of The Raine Group, a global merchant bank focused on technology, media and communications. Prior to founding Raine, he served as Vice Chairman and Global Head of Technology, Media & Telecom Investment Banking at UBS Investment Bank, was a Managing Director at Morgan Stanley and was an attorney at Sullivan & Cromwell in New York and London. Mr. Sine currently serves on the boards of many Raine portfolio companies and subsidiaries. He also serves on the boards of National Public Radio (NPR) (Vice-Chair), ITHAKA, Educational Testing Service (ETS) (Chair), American University and The Manhattan Theatre Club.
About Jason Child
Jason Child’s career spans 30 years across all aspects of global finance and strategy, accounting, capital markets/treasury, IPO execution and investor relations. He has extensive experience in scaling disruptive technologies within enterprise software/SaaS, e-commerce, local commerce, consumer hardware/IOT, and online residential real estate. He most recently served as senior vice-president and CFO at Splunk, a technology company specializing in application management, security and compliance, as well as business and web analytics. Before his executive leadership roles, Jason spent more than 11 years leading various global finance teams at Amazon, and served as CFO of Amazon International. Jason has served as a member of the board of directors of Coupang, Inc., an e-commerce company, since April 2022. He holds B.A. from the Foster School of Business at the University of Washington, where he currently serves on the Global Advisory Board.
About Arm
Arm technology is defining the future of computing. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 230 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, we are enabling artificial intelligence to work everywhere, and in cybersecurity, we are delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.
All information is provided "as is" and without warranty or representation. This document may be shared freely, attributed and unmodified. Arm is a registered trademark of Arm Limited (or its subsidiaries). All brands or product names are the property of their respective holders. © 1995-2022 Arm Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005775/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom